Next-Generation Molecular Diagnostic Platform: Powering Clinical and AI Infrastructure

GeneAtlas

Enabling early and timely disease detection
Ultra-multiplexity and ultra-sensitivity
Cost-effective, convenient and fully accessible solution

Ultra Throughput

100+ multiplexing unlocks maximum diagnostic throughput powered by 4th Gen PCR

Accessibility

Engineered for standard laboratory benchtops
No centralized lab required

Timely

Rapid results empowering clinicians when
personalised treatment decisions matter most

Advancing Life Sciences

GeneAtlas provides a complete, end-to-end IVD ecosystem powered by our proprietary 4th Gen PCR technology.

GeneAtlas Platform
Rapid-cycling molecular diagnostic analyser engineered for the clinic, equiped with automated data processing and reporting

GeneAtlas Universal Kits
Versatile reagents applicable for different scenarios

Clinical Test Kits
Sepsis
Prenatal
Multi-Cancer Early Detection (MCED)

Contact us for custom assay

Workflow in Action

We present a dynamic overview of our GeneAtlas Platform. From DNA partitioning to PCR cycles and target detection.

Bridging the gap between ultra-multiplex screening and rapid diagnostic decision-making

ABOUT MULTERA

Founded in 2025, Multera Limited is dedicated to developing GeneAtlas, a next-generation genomic intelligence platform designed to enable rapid, high-resolution, ultra-multiplex molecular analysis in decentralized clinical settings.

GeneAtlas directly responds to societal needs for earlier disease detection, accessible precision diagnostics, and resilient healthcare infrastructure. By lowering the barrier to high-resolution genomic analysis, the platform extends advanced molecular diagnostics beyond major metropolitan centres. In oncology and prenatal care, earlier and more comprehensive detection improves patient outcomes and reduces long-term healthcare burden. In critical disease like sepsis, earlier identification saves patients’ life.